HTS Biosystems and Dyax Corporation Enter Collaboration Agreement.

HOPKINTON, Mass. -- HTS Biosystems, a developer of high throughput bio-analytical systems, today announced that it has entered into a collaboration with Dyax Corporation, (Nasdaq: DYAX) a biopharmaceutical discovery and development company.

Under the terms of the agreement, Dyax acquired a second FLEXCHIP instrument from HTS. HTS will provide, for a limited time, a special discounted price to collaborators, and licensees of Dyax's antibody, peptide, and protein phage display technology. HTS and Dyax will collaborate to present information derived from the HTS FLEXCHIP system including a FLEXCHIP being displayed at the Dyax booth at the IBC Antibody Engineering Conference, being held from November 30 through December 3, 2004 San Diego.

"We have been working very closely with the Dyax scientists for several years to optimize our System and applications for high-throughput screening of kinetic binding constants of antibodies, peptides, and proteins; and we have succeeded" said Enrico Picozza COO/CTO of HTS Biosystems. "We look forward to seeing the successful results from this joint effort being put to use, and presented on a regular basis at technical conferences."

The HTS FLEXCHIP Kinetic Analysis System is a groundbreaking new platform that combines the data quality of surface plasmon resonance (SPR) with the throughput of advanced chip array technology. Offering increased productivity over conventional SPR methods--and additional advantages over other assay techniques--the FLEXCHIP delivers comparative, quantitative affinity and kinetic ranking of antibodies or other biomolecules in a label-free, parallel format.

About HTS Biosystems

HTS is a recognized developer of next-generation, high-throughput bio-analytical systems and related consumables for the rapidly expanding proteomics, biodefense and medical diagnostic markets. HTS's Proteomatrix(TM) portfolio of intellectual property, collaborations, manufacturing and development capabilities and technologies, allowed it to successfully complete the development and launch of the FLEXCHIP Kinetic Analysis System. With the launch of the FLEXCHIP system complete HTS is uniquely positioned to leverage its Proteomatrix portfolio and infrastructure to commercialize the CHEMIFLEX and PHASEFLEX systems. HTS Biosystems is committed to the ongoing enhancement and expansion of its Proteomatrix portfolio by acquiring and developing promising technologies and collaborating with developers and providers of new complementary technologies. For more information, visit www.htsbiosystems.com.